CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

The Current State of Left Main Percutaneous Coronary Intervention sST2 Predicts Outcome in Chronic Heart Failure Beyond NT−proBNP and High-Sensitivity Troponin T Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular Disease Glucose-lowering Drugs or Strategies, Atherosclerotic Cardiovascular Events, and Heart Failure in People With or at Risk of Type 2 Diabetes: An Updated Systematic Review and Meta-Analysis of Randomised Cardiovascular Outcome Trials Potential protective mechanisms of green tea polyphenol EGCG against COVID-19 Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI Radial Versus Femoral Access for Rotational Atherectomy: A UK Observational Study of 8622 Patients Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes The outcomes of intravascular ultrasound-guided drug-eluting stent implantation among patients with complex coronary lesions: a comprehensive meta-analysis of 15 clinical trials and 8,084 patients Limitations of Repeat Revascularization as an Outcome Measure

Original Research

JOURNAL:ACC Article Link

房颤合并慢性肾病的抗凝策略

CBSMD

Pre-reading

房颤(Atrial fibrillation, AF)和慢性肾脏疾病( chronic kidney disease ,CKD)的多种致病因素常存在共通性,高血压、糖尿病和冠状动脉疾病。当不合并CKD时,对房颤患者开展抗凝治疗是毋庸置疑的,但此做法不适用于房颤合并晚期CKD的患者群(advanced CKD)。随着CKD患者肾功能的下降,缺血性卒中和出血的危险逐渐增加,使抗凝治疗趋向复杂。现存随机对照试验尚不能得出明确辅助临床决策的指南性意见,而观察性研究的结果相互矛盾。在最新JACC综述Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week,作者概述了相关病理生理学机制,总结CKD合并AF的抗凝策略及研究进展, 并就如何在这些患者中使用口服抗凝给出建议

该文核心要点可参阅CBSMD文献导读Anticoagulation in Concomitant CKD and AF”。